Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1201
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: CHAM, Control; Biological · Other
Lead sponsor: Osiris Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Tucson, Arizona • Carlsbad, California • Castro Valley, California + 15 more

Conditions: Urinary Bladder Neoplasms
Interventions: Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab; Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 24
States / cities: Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more

Conditions: Dry Eye Syndrome (DES), Meibomian Gland Dysfunction (Disorder)
Interventions: Manual expression of meibomian glands after thermal eyelid therapy; Device
Lead sponsor: Cleveland Eye Clinic; Other
Eligibility: 50 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Largo, Florida • Brecksville, Ohio

Conditions: Pulmonary Embolism
Interventions: Anticoagulation with heparin, EkoSonicTM Endovascular System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more

Conditions: Thymoma and Thymic Carcinoma
Interventions: octreotide acetate, prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 24
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Partial Epilepsies
Interventions: lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: Not listed
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 40 more

Conditions: Kidney Cancer
Interventions: sunitinib malate, conventional surgery; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anesthesia, Surgical Procedures, Elective
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Loma Linda, California • Miami, Florida + 18 more

Conditions: Brain and Central Nervous System Tumors
Interventions: concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2029
U.S. locations: 271
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more

Conditions: Anxiety
Interventions: Distraction, Usual care; Behavioral · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 3 Years to 5 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
Interventions: Sucraid (sacrosidase) Oral Solution 8500 IU/mL; Biological
Lead sponsor: QOL Medical, LLC; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • Coral Gables, Florida + 13 more

Conditions: Urinary Urgency Incontinence
Interventions: Neuspera Implantable Sacral Nerve Stimulation System; Device
Lead sponsor: Neuspera Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 27 more

Conditions: Proctitis, Ulcerative
Interventions: MAX-002, Placebo, Canasa®; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Dementia With Lewy Bodies
Interventions: Neflamapimod, Placebo; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more

Conditions: Chorea, Huntington
Interventions: Valbenazine, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Intracranial Aneurysm
Interventions: Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device; Device
Lead sponsor: Medtronic Neurovascular Clinical Affairs; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 22
States / cities: Englewood, Colorado • Jacksonville, Florida • Tampa, Florida + 17 more

Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 54
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab; Biological · Other
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more

Conditions: Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Neoplasms, Prostate
Interventions: AI; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Severe Aplastic Anemia
Interventions: cyclosporine, Matched Unrelated Donor Hematopoietic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), methotrexate, fludarabine, cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST); Drug · Procedure · Radiation
Lead sponsor: Michael Pulsipher; Other
Eligibility: Up to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more

Conditions: Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
Interventions: SJ4 connector and RV high voltage SJ4 lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aortic Coarctation
Interventions: Treatment of Aortic Wall Injury; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Search by objective public record fields.

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Comparison of Usual Care and Distraction (Tablet) in Children 3-5 Years Old

7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

VA Augmentation and Switching Treatments for Improving Depression Outcomes

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Investigation of Impact of AI on Prostate Cancer Workflow

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta